Congress ties children's hospital funding to gender-care restrictions

What it does

This bill reauthorizes federal funding for children's hospitals' graduate medical education (GME) programs through 2030, allocating $124 million annually for direct GME support and $261 million annually for indirect costs. However, it adds a controversial condition: starting in 2026, children's hospitals lose this federal funding if they provide gender-affirming medical procedures or puberty-blocking medications to minors, with narrow exceptions for treating precocious puberty and certain intersex conditions.

Why we flagged it

The bill's primary functional mechanism is not GME reauthorization per se, but rather a federal funding condition that restricts specific medical treatments at children's hospitals. The reauthorization is the vehicle; the restriction is the substance.

• Gender-affirming care restriction (Section 340E subsection) is substantively unrelated to GME program reauthorization and funding mechanics. It is a clinical practice prohibition embedded in a funding statute.

What the text implies

• The bill creates a federal enforcement mechanism for clinical practice standards without explicit FDA/medical board oversight, potentially bypassing established medical credentialing and peer-review processes.
• Hospitals may face legal liability if they cannot definitively prove a minor's sex-development status meets the narrow exceptions, creating a chilling effect on treatment even for qualifying conditions.

The full analysis lists 5 implications of this text.

Who stands to gain

Children's hospitals (conditional on compliance); Pharmaceutical companies (indirectly, if restrictions reduce certain medication use)